Key result
Alirocumab plus statin achieving very low LDL-C cuts major cardiovascular events ~28% versus statin alone.
Answers are grounded in this paper and cite their sources.
For the podcast associated with this article, please visit https://academic.oup.com/eurheartj/pages/Podcasts. The mechanisms linking dyslipidaemias to atherosclerotic cardiovascular disease (ASCVD) are complex and only partially known.1–5 This Focus Issue on dyslipidaemias contains a State of the Art Review entitled ‘High-density lipoprotein revisited: biological functions and clinical relevance’ by Arnold von Eckardstein from the University Hospital Zurich and University of Zurich in Switzerland, and colleagues. The authors note that previous interest in high-density lipoproteins (HDLs) focused on their possible protective role in ASCVD.6 Evidence from genetic studies and randomized trials, however, questioned that the inverse association of HDL-cholesterol (HDL-C) is causal. This review aims to provide an update on the role of HDL in health and disease, also beyond ASCVD. Through evolution from invertebrates, HDLs are the principal lipoproteins, while apolipoprotein B-containing lipoproteins first developed in vertebrates. HDLs transport cholesterol and other lipids between different cells like a reusable ferry, but serve many other functions including communication with cells and the inactivation of biohazards such as bacterial lipopolysaccharides. These functions are exerted by entire HDL particles or distinct proteins or lipids carried by HDL, rather than by its cholesterol cargo measured as HDL-C. Neither does HDL-C measurement reflect the efficiency of reverse cholesterol transport. Recent studies indicate that functional measures of HDL, notably cholesterol efflux capacity, numbers of HDL particles, or distinct HDL proteins, are better predictors of ASCVD events than HDL-C. Low HDL-C levels are related observationally, but also genetically, to increased risks of infectious diseases, death during sepsis, diabetes mellitus, and chronic kidney disease. Additional, but only observational, data indicate associations of low HDL-C with various autoimmune diseases, and cancers, as well as all-cause mortality. Conversely, extremely high HDL-C levels are associated with an increased risk of age-related macular degeneration (also genetically), infectious disease, and all-cause mortality. HDL encompasses dynamic multimolecular and multifunctional lipoproteins that probably emerged during evolution to serve several physiological roles and prevent or heal pathologies beyond ASCVD. For any clinical exploitation of HDL, the indirect marker HDL-C must be replaced by direct biomarkers reflecting the causal role of HDL in the respective disease. Long-term, placebo-controlled cholesterol-lowering trials have demonstrated legacy effects (clinical benefits that persist or emerge after the trial has ended). In a Fast Track Clinical Research article entitled ‘Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial’, Gregory Schwartz from the University of Colorado School of Medicine in Aurora, CO, USA, and colleagues note that it is unknown whether legacy effects follow a short period of very low LDL-C levels achieved with statin plus a PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor.7 In ∼19 000 post-acute coronary syndrome patients, the ODYSSEY OUTCOMES trial compared the PCSK9 inhibitor alirocumab with placebo, each added to high-intensity or maximum-tolerated statin therapy. Patients with two consecutive LDL-C levels <0.39 mmol/L (15 mg/dL) on alirocumab had blinded placebo substitution for the remainder of the trial with continued statin treatment. In post-hoc analyses, major adverse cardiovascular events (MACE) in these patients were compared with MACE in propensity score-matched patients from the placebo group with similar baseline characteristics and study medication adherence. In the alirocumab group, 730 patients had blinded placebo substitution at a median 8.3 months from randomization after a median 6.0 months with LDL-C <0.39 mmol/L. They were matched to 1460 placebo patients. Over a median follow-up of 2.8 years, MACE occurred in 6.4% alirocumab patients with limited duration, very low achieved LDL-C vs. 8.4% matched placebo patients (treatment hazard ratio 0.72; P = 0.047) (Figure 1). A short period of very low LDL-cholesterol levels achieved with statin and alirocumab is associated with a prolonged reduction of cardiovascular risk after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomized trial.7 Schwartz et al. conclude that a short period of LDL-C levels <0.39 mmol/L (15 mg/dL) achieved with statin and alirocumab, followed by statin monotherapy, is associated with lower risk of MACE than statin monotherapy throughout the observation period. Clinical benefit persists for several years. The contribution is accompanied by an Editorial by Jacques Genest from McGill University Health Center in Montreal, Canada.8 Genest notes that a clinical consensus statement of the Association for Acute CardioVascular Care, in collaboration with the European Association of Preventive Cardiology already recommends the approach of ‘strike early and strike strong’. The question remains of whether the approach of sustained intensive (and costly) lipid-lowering treatment following an acute coronary syndrome can be safely substituted for a pulse of very intensive LDL-C lowering, followed by a chase of ‘standard’ statin therapy. The assessment of dyslipidaemias in children is a topic of growing interest.9–13 In a Clinical Research article entitled ‘Lipoprotein(a) levels in children with suspected familial hypercholesterolaemia: a cross-sectional study’, Lotte de Boer from the Amsterdam UMC at the University of Amsterdam in the Netherlands, and colleagues indicate that familial hypercholesterolaemia (FH) predisposes children to the early initiation of atherosclerosis and is preferably diagnosed by DNA analysis.14 Yet, in many children with a clinical presentation of FH, no mutation is found. Adult data show that high levels of lipoprotein(a) [Lp(a)] may underlie a clinical presentation of FH, as the cholesterol content of Lp(a) is included in conventional LDL cholesterol measurements. As this is limited to adult data, Lp(a) levels in children with and without (clinical) FH were evaluated. Children were eligible if they visited the paediatric lipid clinic (1989–2020) and if Lp(a) measurement and DNA analysis were performed. In total, 2721 children (mean age 10.3 years) were included and divided into four groups: 1931 children with definite FH (mutation detected), 290 unaffected siblings/normolipidaemic controls (mutation excluded), 108 children with probable FH (clinical presentation, mutation not detected), and 392 children with probable non-FH (no clinical presentation, mutation not excluded). In children with probable FH, 32% were found to have high Lp(a) compared with 10% both in children with definite FH (P = 0.017) and unaffected siblings (P = 0.002), respectively. de Boer and colleagues conclude that Lp(a) is significantly higher and more frequently elevated in children with probable FH compared with children with definite FH and unaffected siblings, suggesting that high Lp(a) levels may underlie the clinical presentation of FH when no FH-causing mutation is found. Both performing DNA analysis and measuring Lp(a) in all children suspected of FH is recommended to assess possible LDL-C overestimation related to increased Lp(a). The contribution is accompanied by an Editorial by Maurizio Averna and Angelo Cefalù from the Università degli Studi di Palermo in Italy.15 The authors conclude that de Boer et al. highlight the role of Lp(a) in eliciting an FH clinical phenotype in children and the need for implementing the Lp(a) measurement in a paediatric setting. These results may help to inform our clinical approach to the diagnosis and management of paediatric hypercholesterolaemia. Cholesterol carried in triglyceride (TG)-rich lipoproteins, also called remnant cholesterol, is being increasingly acknowledged as an important causal risk factor for atherosclerosis. Elevated remnant cholesterol, marked by elevated plasma TGs, is associated causally with an increased risk of ASCVD.16–19 The association with cause-specific mortality is, however, unclear. In a Clinical Research article entitled ‘Elevated remnant cholesterol, plasma triglycerides, and cardiovascular and non-cardiovascular mortality’, Benjamin Wadström from the Copenhagen University Hospital in Denmark, and colleagues tested the hypothesis that elevated remnant cholesterol and plasma TGs are associated with increased mortality from cardiovascular disease, cancer, and other causes.20 Using a contemporary population-based cohort, > 87 000 individuals from the Copenhagen General Population Study aged 20–69 years at baseline in 2003–2015 were included. During up to 13 years of follow-up, 687 individuals died from cardiovascular disease, 1594 from cancer, and 856 from other causes, according to the National Danish Causes of Death Registry. In individuals with remnant cholesterol ≥1.0 mmol/L (≥39 mg/dL; 22% of the population) compared with those with levels <0.5 mmol/L (<19 mg/dL), multivariable-adjusted mortality hazard ratios were 2.2 for cardiovascular disease, 1.0 for cancer, and 2.1 for other causes. Exploratory analysis of the cause of death subcategories showed corresponding hazard ratios of 4.4 for ischaemic heart disease, 8.4 for infectious diseases, and 9.1 for endocrinological diseases. Results for plasma TGs >2 vs. < 1 mmol/L (>177 vs. < 89 mg/dL) were similar. The authors conclude that remnant cholesterol of ≥1 mmol/L (39 mg/dL), present in 22% of the population, and plasma TGs of ≥2 mmol/L (177 mg/dL), present in 28% of the population, are associated with two-fold mortality from cardiovascular and other causes, but not from cancer. The contribution is accompanied by an Editorial by Paulina Stürzebecher, Ulrich Laufs, and Julius Katzmann from the Universitätsklinikum Leipzig in Germany.21 They note that an important novel finding of the study relates to the association of serum TG with total mortality. The relationship between calculated ‘remnant’ cholesterol and other mortality was attenuated after adjustment for body mass index, waist circumference, and diabetes, because these conditions are associated with higher serum TGs. The relationship was ‘nominally attributed to increased mortality from all other mortality subcategories, except for mental disorders and respiratory diseases, and especially to infectious and endocrinological diseases’. Interestingly, there was no association of TG with cancer mortality. The observations are not yet mechanistically explained and set the stage for further studies to understand the relationship of serum TG with different non-cardiovascular diseases. With emerging therapeutic options to reduce TG-rich lipoproteins, this field of research is likely to become increasingly important. The interaction between dyslipidaemias and inflammation in the pathogenesis of ASCVD is complex.22,23 In a Clinical Research article entitled ‘Lipoprotein(a) is linked to atherothrombosis and aortic valve stenosis independent of C-reactive protein’, Peter Thomas from the Copenhagen University Hospital—Herlev and Gentofte in Denmark, and colleagues hypothesized that high Lp(a) is a main driver for the risk of ASCVD, myocardial infarction, and aortic valve stenosis irrespective of C-reactive protein (CRP) levels.24 A total of more than 68 000 individuals from the Copenhagen General Population Study, a prospective cohort study, were included. During a median follow-up of 8.1 years, > 5000 individuals developed ASCVD, 2432 myocardial infarction, and 1220 aortic valve stenosis. The risk of ASCVD, myocardial infarction, and aortic valve stenosis increased with higher values of both Lp(a) and CRP. For individuals with Lp(a) in the 91st–100th percentiles vs. the 1st–33rd percentiles, the multivariable-adjusted hazard ratio for ASCVD was 1.61 for those with CRP <2 mg/L and 1.57 for those with CRP ≥2 mg/L (P for interaction = 0.87). The corresponding values were 2.08 and 1.65 for myocardial infarction, and 2.01 and 1.73 for aortic valve stenosis, respectively (P for interaction = 0.15 and = 0.18) (Figure 2). Lipoprotein(a) is linked to atherothrombosis and aortic valve stenosis independent of C-reactive protein. ASCVD, atherosclerotic cardiovascular disease; CRP, C-reactive protein; HR, hazard ratio; CI, confidence interval.24 Thomas and colleagues conclude that high Lp(a) is a main driver for the risk of ASCVD, myocardial infarction, and aortic valve stenosis independent of CRP levels. The contribution is accompanied by an Editorial by Carl Orringer from the University of Miami Miller School of Medicine in Florida, FL, USA.25 Orringer concludes that two RNA-silencing drugs, olpasiran and SLN360, have been shown to produce a > 95% reduction in circulating Lp(a) concentration and, after initial injections at baseline and 3 months, result in persistent Lp(a) lowering when administered every 6 months. While the current approach to patients with elevated Lp(a) levels rests on evidence-based modification of conventional risk factors, the results of outcomes trials for these Lp(a) therapeutics will determine if pharmacological intensive Lp(a) reduction can be safely accomplished and favourably affect cardiovascular outcomes. In a Clinical Research article entitled ‘Long-term cardiometabolic health in people born after assisted reproductive technology: a multi-cohort analysis’, Ahmed Elhakeem from the MRC Integrative Epidemiology Unit at the University of Bristol in Bristol, UK, and colleagues examined associations of assisted reproductive technology (ART) conception (vs. natural conception: NC) with offspring cardiometabolic health outcomes and whether these differ with age.26 Differences in systolic (SBP) and diastolic blood pressure (DBP), heart rate (HR), lipids, and hyperglycaemic/insulin resistance markers were examined using multiple linear regression models in 14 population-based birth cohorts in Europe, Australia, and Singapore, and results were combined using meta-analysis. Change in cardiometabolic outcomes from 2 to 26 years was examined using trajectory modelling of four cohorts with repeated measures. A total of ∼36 000 offspring (654 ART) were included in the meta-analysis. Mean age ranged from 13 months to 27 years but was <10 years in 11/14 cohorts. Meta-analysis found no statistical difference in SBP, DBP, or HR. Total cholesterol (2.59%), HDL-C (4.16%), and LDL-C (4.95%) were statistically significantly higher in ART-conceived vs. NC offspring. No statistical difference was seen for TG, glucose, insulin, and glycated haemoglobin. The authors conclude that these findings of small and frequently statistically non-significant differences in offspring cardiometabolic outcomes should reassure people receiving ART. Longer term follow-up is warranted to investigate changes throughout adulthood in the risks of hypertension, dyslipidaemia, and pre-clinical and clinical cardiovascular disease. The manuscript is accompanied by an Editorial by Claire Lawley, Gemma Figtree, and Clare Arnott from the University of Sydney in Australia.27 The authors highlight that the previous assertion that young adults born via ART may be at high cardiometabolic risk is challenged by this work, which benefits from a large sample size and rigorous statistical methodology. It gives the parents of children born from ART a degree of confidence regarding the cardiometabolic health of their offspring through childhood and the early years of adolescence. Hopefully, The Assisted Reproductive Technology and Future Health (ART-Health) Cohort Collaboration, will be able to provide additional important information during longer follow-up. The editors hope that this issue of the European Heart Journal will be of interest to its readers. Dr. Crea reports speaker fees from Abbott, Amgen, Astra Zeneca, BMS, Chiesi, Daiichi Sankyo, Menarini outside the submitted work. With thanks to Amelia Meier-Batschelet, Johanna Huggler, and Martin Meyer for help with compilation of this article.
No takes yet. Share an insight, caveat, or question.
Filippo Crea (2023) conducted an editorial in Dyslipidaemias and atherosclerotic cardiovascular disease. Lipid-lowering therapy and lipoprotein biomarkers (HDL, Lp(a), remnant cholesterol, PCSK9 inhibition) was evaluated on Major adverse cardiovascular events, atherosclerotic cardiovascular disease, and cause-specific mortality. Transiently achieving LDL-C <0.39 mmol/L with alirocumab plus statin reduced major cardiovascular events vs statin alone, while elevated Lp(a) and remnant cholesterol increased ASCVD risk.
Synapse has enriched 10 related papers. Consider them for comparative context: